A Phase 1 interventional study of Olaparib and Paclitaxel in Advanced Solid Tumours, sponsored by AstraZeneca. Completed at 3 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-07-31.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 2 parts phase I, open label trial of olaparib monotherapy and olaparib in combination with paclitaxel in patients with solid tumours. Part A will assess the single and multiple dose pharmacokinetics of olaparib monotherapy and multiple dose pharmacokinetics of olaparib in combination with paclitaxel. Part B will assess the safety of multiple doses of olaparib in Cohort 1 and of olaparib when co-administered with paclitaxel in Cohort 2
Part A will access the pharmacokinetics of olaparib: Cohort 1 will investigate the single and multiple dose pharmacokinetics of olaparib following 300mg bd monotherapy dose(s); Cohort 2 will investigate the single and multiple dose pharmacokinetics of olaparib following 100mg bd monotherapy dose(s) and the multiple dose pharmacokinetics in the presence of co-administered paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle).
In Part B: Safety profile of olaparib 300mg bd as monotherapy and olaparib 100mg bd in combination with weekly paclitaxel will also be investigated in Chinese patients.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day
Drug: Olaparib
Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)
Drug: Paclitaxel · Drug: Olaparib
Tablet-150mg, Oral
Injection
Tablet-100mg, Oral
Single Dose PK Parameter--Cmax
Single dose PK parameter summary for olaparib in monotherapy by dose - Cmax (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Single Dose PK Parameter--AUC
Single dose PK parameter summary for olaparib in monotherapy by dose - AUC (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Single Dose PK Parameter--tmax
Single dose PK parameter summary for olaparib in monotherapy by dose - tmax (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Single Dose PK Parameter--t1/2, λz
Single dose PK parameter summary for olaparib in monotherapy by dose - t1/2, λz (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Single Dose PK Parameter--Vz/F
Single dose PK parameter summary for olaparib in monotherapy by dose - Vz/F (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Single Dose PK Parameter--CL/F
Single dose PK parameter summary for olaparib in monotherapy by dose - CL/F (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 (Day 2) and 48 h (Day 3)
Steady State PK Parameter--Cmax, ss and Cmin, ss at Day 8
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - Cmax, ss and Cmin, ss (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
Steady State PK Parameter--AUCss at Day 8
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - AUC (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
Steady State PK Parameter--tmax, ss at Day 8
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - tmax, ss (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
Steady State PK Parameter--RAC and TCP at Day 8
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - RAC and TCP (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
Steady State PK Parameter--Cmax, ss and Cmin, ss at Day 9
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - Cmax, ss and Cmin, ss (PK analysis set)
Time frame: PK samples were collected pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 9
Steady State PK Parameter--AUCss at Day 9
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - AUC (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 9
Steady State PK Parameter--tmax, ss at Day 9
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - tmax, ss (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 9
Steady State PK Parameter--CLss/F at Day 8
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - CLss/F (PK analysis set)
Time frame: PK samples were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post morning dose of Day 8
This study was performed at 3 study centres in China.The first patient entered the study on 10 June 2015 and the last patient completed Part A of the study on 02 August 2016, and the date of last patient last visit in Part B was 28 April 2017.
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 20 | 16 |
| Received olaparib | 20 | 16 |
| Received paclitaxel | 0 | 16 |
| Completed | 19 | 15 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 19 | 15 |
| Received olaparib | 19 | 15 |
| Received paclitaxel | 0 | 14 |
| Completed | 9 | 7 |
| Not completed | 10 | 8 |
| Withdrew: Meet study-specific withdrawal criteria | 6 | 6 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 1 | 0 |
Single dose PK parameter summary for olaparib in monotherapy by dose - Cmax (PK analysis set)
| µg/mL | Cohort 1 | Cohort 2 |
|---|---|---|
| Single Dose PK Parameter--Cmax | 6.875 ± 39.70 | 2.972 ± 41.80 |
Single dose PK parameter summary for olaparib in monotherapy by dose - AUC (PK analysis set)
| µg*h/mL | Cohort 1 | Cohort 2 |
|---|---|---|
| AUC0-12 | 31.68 ± 52.97 | 10.86 ± 61.60 |
| AUC0-t | 36.37 ± 59.58 | 12.63 ± 75.42 |
| AUC | 36.53 ± 59.86 | 12.75 ± 76.70 |
Single dose PK parameter summary for olaparib in monotherapy by dose - tmax (PK analysis set)
| hour | Cohort 2 | Cohort 1 |
|---|---|---|
| Single Dose PK Parameter--tmax | 1.95 ± 61.60 | 1.50 (0.50 to 4.00) |
Single dose PK parameter summary for olaparib in monotherapy by dose - t1/2, λz (PK analysis set)
| hour | Cohort 2 | Cohort 1 |
|---|---|---|
| Single Dose PK Parameter--t1/2, λz | 7.165 ± 2.542 | 6.519 ± 1.346 |
Single dose PK parameter summary for olaparib in monotherapy by dose - Vz/F (PK analysis set)
| L | Cohort 2 | Cohort 1 |
|---|---|---|
| Single Dose PK Parameter--Vz/F | 88.32 ± 44.04 | 74.78 ± 75.41 |
Single dose PK parameter summary for olaparib in monotherapy by dose - CL/F (PK analysis set)
| L/h | Cohort 2 | Cohort 1 |
|---|---|---|
| Single Dose PK Parameter--CL/F | 9.217 ± 4.531 | 8.107 ± 6.689 |
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - Cmax, ss and Cmin, ss (PK analysis set)
| µg/mL | Cohort 1 | Cohort 2 (Olaparib Alone) |
|---|---|---|
| Cmax, ss | 8.268 ± 35.02 | 3.752 ± 40.99 |
| Cmin, ss | 0.7996 ± 117.8 | 0.3162 ± 129.4 |
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - AUC (PK analysis set)
| µg*h/mL | Cohort 1 | Cohort 2, Olaparib Alone |
|---|---|---|
| AUCss | 43.95 ± 48.43 | 16.73 ± 61.38 |
| AUC0-t | 43.91 ± 48.47 | 16.68 ± 61.30 |
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - tmax, ss (PK analysis set)
| hour | Cohort 1 | Cohort 2, Olaparib Alone |
|---|---|---|
| Steady State PK Parameter--tmax, ss at Day 8 | 1.50 (0.97 to 3.00) | 2.00 (0.97 to 4.02) |
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - RAC and TCP (PK analysis set)
| Ratio | Cohort 1 | Cohort 2, Olaparib Alone |
|---|---|---|
| RAC | 1.436 ± 0.2081 | 1.565 ± 0.2984 |
| TCP | 1.253 ± 0.2150 | 1.349 ± 0.3349 |
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - Cmax, ss and Cmin, ss (PK analysis set)
| µg/mL | Cohort 2(Olaparib 100 mg + Paclitaxel) |
|---|---|
| Cmax, ss | 3.031 ± 56.14 |
| Cmin, ss | 0.1915 ± 125.2 |
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - AUC (PK analysis set)
| µg*h/mL | Cohort 2(Olaparib 100 mg + Paclitaxel) |
|---|---|
| AUCss | 12.44 ± 57.46 |
| AUC0-t | 12.42 ± 57.36 |
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - tmax, ss (PK analysis set)
| hour | Cohort 2(Olaparib 100 mg + Paclitaxel) |
|---|---|
| Steady State PK Parameter--tmax, ss at Day 9 | 1.48 ± 61.38 |
Steady state pharmacokinetic parameter summary for olaparib by dose and visit after multiple doses - CLss/F (PK analysis set)
| L/h | Cohort 1 | Cohort 2, Olaparib Alone |
|---|---|---|
| Steady State PK Parameter--CLss/F at Day 8 | 7.512 ± 3.418 | 6.745 ± 2.923 |
Collected over Includes AEs with an onset date between the first dose date in the appropriate Part and the day before first dose in Part B (for Part A only), or 30 days following the date of last dose of study medication if the subject discontinued.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 Part A | — | 0/20 (0%) | 11/20 (55%) |
| Cohort 2 Part A, Olaparib 100 mg | — | 0/16 (0%) | 8/16 (50%) |
| Cohort 2 Part A, Olaparib 100mg in Combination With Paclitaxel | — | 4/16 (25%) | 16/16 (100%) |
| Cohort 1 Part B | — | 0/19 (0%) | 18/19 (94.7%) |
| Cohort 2 Part B, Olaparib 300 mg Monotherapy | — | 0/2 (0%) | 2/2 (100%) |
| Cohort 2 Part B, Olaparib 100mg in Combination With Paclitaxel | — | 1/15 (6.7%) | 15/15 (100%) |
| Event | Cohort 1 Part A | Cohort 2 Part A, Olaparib 100 mg | Cohort 2 Part A, Olaparib 100mg in Combination With Paclitaxel | Cohort 1 Part B | Cohort 2 Part B, Olaparib 300 mg Monotherapy | Cohort 2 Part B, Olaparib 100mg in Combination With Paclitaxel |
|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/20 | 0/16 | 3/16 | 0/19 | 0/2 | 1/15 |
| Liver injuryHepatobiliary disorders | 0/20 | 0/16 | 1/16 | 0/19 | 0/2 | 0/15 |
| Event | Cohort 1 Part A | Cohort 2 Part A, Olaparib 100 mg | Cohort 2 Part A, Olaparib 100mg in Combination With Paclitaxel | Cohort 1 Part B | Cohort 2 Part B, Olaparib 300 mg Monotherapy | Cohort 2 Part B, Olaparib 100mg in Combination With Paclitaxel |
|---|---|---|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 3/20 | 1/16 | 12/16 | 8/19 | 1/2 | 15/15 |
| NeutropeniaBlood and lymphatic system disorders | 1/20 | 1/16 | 11/16 | 8/19 | 1/2 | 14/15 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/20 | 0/16 | 9/16 | 0/19 | 0/2 | 1/15 |
| NeurotoxicityNervous system disorders | 0/20 | 0/16 | 3/16 | 0/19 | 0/2 | 8/15 |
| FatigueGeneral disorders | 0/20 | 2/16 | 8/16 | 5/19 | 0/2 | 2/15 |
| AnaemiaBlood and lymphatic system disorders | 3/20 | 2/16 | 6/16 | 7/19 | 1/2 | 7/15 |
| Upper respiratory tract infectionInfections and infestations | 0/20 | 0/16 | 1/16 | 2/19 | 0/2 | 5/15 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/20 | 0/16 | 4/16 | 0/19 | 0/2 | 5/15 |
| Alanine aminotransferase increasedInvestigations | 0/20 | 1/16 | 3/16 | 4/19 | 0/2 | 5/15 |
| NauseaGastrointestinal disorders | 4/20 | 2/16 | 5/16 | 4/19 | 0/2 | 2/15 |
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 47.7 ± 10.43 | 49.3 ± 9.49 | 48.4 ± 9.92 |
| Age, Customized(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| <50 years | 11 | 9 | 20 |
| ≥50 <65 years | 9 | 6 | 15 |
| ≥65 <75 years | 0 | 1 | 1 |
| ≥75 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 13 | 15 | 28 |
| Male | 7 | 1 | 8 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Chinese | 20 | 16 | 36 |
| Height(cm) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 164.9 ± 6.25 | 160.3 ± 4.81 | 162.8 ± 6.04 |
| Weight(kg) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 64.8 ± 10.35 | 60.9 ± 8.71 | 63.1 ± 9.71 |
| Body mass index(kg/m2) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 23.91 ± 4.144 | 23.78 ± 3.599 | 23.85 ± 3.857 |
Ran from Jun 2015 to primary completion in Jul 2016, 13 months.
Results were first posted in Sep 2018, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib